Chiome Bioscience Inc. (TYO:4583)

Market Cap	9.08B
Revenue (ttm)	780.81M
Net Income (ttm)	-1.02B
Shares Out	67.76M
EPS (ttm)	-17.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	713,700
Average Volume	1,322,120
Open	133.00
Previous Close	133.00
Day's Range	131.00 - 135.00
52-Week Range	75.00 - 304.00
Beta	0.38
RSI	46.24
Earnings Date	May 12, 2025

About Chiome Bioscience

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. The company also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 53
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4583

Financial Performance

In 2024, Chiome Bioscience's revenue was 780.81 million, an increase of 14.41% compared to the previous year's 682.46 million. Losses were -1.02 billion, -16.33% less than in 2023.